By Zhong Nan | China Daily | Updated: 2026-01-06 A Simcere employee arranges products at a production facility in Haikou, Hainan province. SUN SHI...

Envafolimab, a subcutaneous PD-L1 antibody developed by Simcere Zaiming in collaboration with Alphamab Oncology (9966.HK) and 3D Medicines (1244.HK) i...

December 23, 2025 – Simcere Zaiming, an oncology-focused bipharmaceutical company and a subsidiary of Simcere Pharmaceutical Group (2096.HK)announced ...

• Ipsen gains exclusive global rights, outside of Greater China, for development, manufacturing and commercialization of SIM0613, a LRR...